599 related articles for article (PubMed ID: 25945834)
1. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
[TBL] [Abstract][Full Text] [Related]
2. SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A.
Hung MH; Wang CY; Chen YL; Chu PY; Hsiao YJ; Tai WT; Chao TT; Yu HC; Shiau CW; Chen KF
Oncotarget; 2016 Jan; 7(1):638-55. PubMed ID: 26575017
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of SET oncoprotein is associated with tumor progression and poor prognosis in human gastric cancer.
Yuan X; Zhang T; Zheng X; Zhang Y; Feng T; Liu P; Sun Z; Qin S; Liu X; Zhang L; Song J; Liu Y
Oncol Rep; 2017 Sep; 38(3):1733-1741. PubMed ID: 28677734
[TBL] [Abstract][Full Text] [Related]
4. [Expression of AKT2, cyclin D1, and MMP-9 and their correlations to clinicopathologic features of non-small cell lung cancer].
Wang J; Miao LJ; Wu YM; Wu YJ; Wang XC
Ai Zheng; 2006 Jan; 25(1):69-72. PubMed ID: 16405753
[TBL] [Abstract][Full Text] [Related]
5. B-Myb Mediates Proliferation and Migration of Non-Small-Cell Lung Cancer via Suppressing IGFBP3.
Fan X; Wang Y; Jiang T; Cai W; Jin Y; Niu Y; Zhu H; Bu Y
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772705
[TBL] [Abstract][Full Text] [Related]
6. L1 cell adhesion molecule promotes tumorigenicity and metastatic potential in non-small cell lung cancer.
Hai J; Zhu CQ; Bandarchi B; Wang YH; Navab R; Shepherd FA; Jurisica I; Tsao MS
Clin Cancer Res; 2012 Apr; 18(7):1914-24. PubMed ID: 22307136
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
Hu X; Garcia C; Fazli L; Gleave M; Vitek MP; Jansen M; Christensen D; Mulholland DJ
Sci Rep; 2015 Nov; 5():15182. PubMed ID: 26563471
[TBL] [Abstract][Full Text] [Related]
8. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
9. DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway.
Wang Z; Luo Z; Zhou L; Li X; Jiang T; Fu E
Cancer Sci; 2015 Oct; 106(10):1303-12. PubMed ID: 26212035
[TBL] [Abstract][Full Text] [Related]
10. PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis.
Zhou X; Updegraff BL; Guo Y; Peyton M; Girard L; Larsen JE; Xie XJ; Zhou Y; Hwang TH; Xie Y; Rodriguez-Canales J; Villalobos P; Behrens C; Wistuba II; Minna JD; O'Donnell KA
Cancer Res; 2017 Jan; 77(1):187-197. PubMed ID: 27821484
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
12. Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9.
Dong QZ; Wang Y; Tang ZP; Fu L; Li QC; Wang ED; Wang EH
Am J Pathol; 2013 Mar; 182(3):954-64. PubMed ID: 23306155
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
[TBL] [Abstract][Full Text] [Related]
14. miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway.
Yu SH; Zhang CL; Dong FS; Zhang YM
J Cell Biochem; 2015 Feb; 116(2):268-76. PubMed ID: 25187230
[TBL] [Abstract][Full Text] [Related]
15. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
16. Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development.
Sun C; Huang C; Li S; Yang C; Xi Y; Wang L; Zhang F; Fu Y; Li D
Oncotarget; 2016 Feb; 7(7):8341-59. PubMed ID: 26840018
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of astrocyte-elevated gene-1 is closely correlated with poor prognosis in human non-small cell lung cancer and mediates its metastasis through up-regulation of matrix metalloproteinase-9 expression.
Sun S; Ke Z; Wang F; Li S; Chen W; Han A; Wang Z; Shi H; Wang LT; Chen X
Hum Pathol; 2012 Jul; 43(7):1051-60. PubMed ID: 22204714
[TBL] [Abstract][Full Text] [Related]
18. ARMC8α promotes proliferation and invasion of non-small cell lung cancer cells by activating the canonical Wnt signaling pathway.
Xie C; Jiang G; Fan C; Zhang X; Zhang Y; Miao Y; Lin X; Wu J; Wang L; Liu Y; Yu J; Yang L; Zhang D; Xu K; Wang E
Tumour Biol; 2014 Sep; 35(9):8903-11. PubMed ID: 24894675
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer.
Cristóbal I; Caramés C; Rincón R; Manso R; Madoz-Gúrpide J; Torrejón B; González-Alonso P; Rojo F; García-Foncillas J
Oncotarget; 2017 Jun; 8(25):40169-40180. PubMed ID: 27517624
[TBL] [Abstract][Full Text] [Related]
20. Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer.
Chen B; Tan Z; Gao J; Wu W; Liu L; Jin W; Cao Y; Zhao S; Zhang W; Qiu Z; Liu D; Mo X; Li W
J Exp Clin Cancer Res; 2015 Oct; 34():126. PubMed ID: 26490682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
